CN111454993B - Semen cassiae fermentation product and application thereof - Google Patents
Semen cassiae fermentation product and application thereof Download PDFInfo
- Publication number
- CN111454993B CN111454993B CN202010293704.8A CN202010293704A CN111454993B CN 111454993 B CN111454993 B CN 111454993B CN 202010293704 A CN202010293704 A CN 202010293704A CN 111454993 B CN111454993 B CN 111454993B
- Authority
- CN
- China
- Prior art keywords
- fermentation
- parts
- fermentation product
- cassia seed
- cassia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000855 fermentation Methods 0.000 title claims abstract description 125
- 230000004151 fermentation Effects 0.000 title claims abstract description 125
- 210000000582 semen Anatomy 0.000 title claims abstract description 17
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 46
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 46
- 239000000203 mixture Substances 0.000 claims abstract description 27
- 239000002994 raw material Substances 0.000 claims abstract description 22
- 230000001580 bacterial effect Effects 0.000 claims abstract description 18
- 239000007788 liquid Substances 0.000 claims abstract description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 16
- 244000046052 Phaseolus vulgaris Species 0.000 claims abstract description 13
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims abstract description 13
- 235000015099 wheat brans Nutrition 0.000 claims abstract description 13
- 239000000843 powder Substances 0.000 claims abstract description 11
- 235000019764 Soybean Meal Nutrition 0.000 claims abstract description 10
- 239000004455 soybean meal Substances 0.000 claims abstract description 10
- 238000001914 filtration Methods 0.000 claims abstract description 9
- 238000002156 mixing Methods 0.000 claims abstract description 9
- 238000001694 spray drying Methods 0.000 claims abstract description 8
- 230000001954 sterilising effect Effects 0.000 claims abstract description 8
- 238000003756 stirring Methods 0.000 claims abstract description 8
- 239000012752 auxiliary agent Substances 0.000 claims description 23
- 241000228245 Aspergillus niger Species 0.000 claims description 17
- 235000014663 Kluyveromyces fragilis Nutrition 0.000 claims description 17
- 241000186869 Lactobacillus salivarius Species 0.000 claims description 17
- 244000253911 Saccharomyces fragilis Species 0.000 claims description 17
- 235000018368 Saccharomyces fragilis Nutrition 0.000 claims description 17
- 229940031154 kluyveromyces marxianus Drugs 0.000 claims description 17
- 229930006000 Sucrose Natural products 0.000 claims description 13
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 13
- 238000000605 extraction Methods 0.000 claims description 11
- 235000020183 skimmed milk Nutrition 0.000 claims description 11
- 239000005720 sucrose Substances 0.000 claims description 9
- 239000008280 blood Substances 0.000 claims description 8
- 210000004369 blood Anatomy 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 210000004185 liver Anatomy 0.000 claims description 5
- 150000002632 lipids Chemical class 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 230000000844 anti-bacterial effect Effects 0.000 claims description 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 25
- 230000000694 effects Effects 0.000 abstract description 20
- 238000000034 method Methods 0.000 abstract description 17
- 244000005700 microbiome Species 0.000 abstract description 15
- 239000004480 active ingredient Substances 0.000 abstract description 5
- 230000003993 interaction Effects 0.000 abstract description 5
- 230000008569 process Effects 0.000 abstract description 5
- 230000000813 microbial effect Effects 0.000 abstract description 3
- 239000000654 additive Substances 0.000 abstract 1
- 239000000047 product Substances 0.000 description 42
- 230000000052 comparative effect Effects 0.000 description 12
- 239000000284 extract Substances 0.000 description 12
- 229960004793 sucrose Drugs 0.000 description 12
- 229940079593 drug Drugs 0.000 description 10
- 238000001514 detection method Methods 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 8
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 8
- 150000004056 anthraquinones Chemical class 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 229940126680 traditional chinese medicines Drugs 0.000 description 6
- -1 anthraquinone compound Chemical class 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 206010010774 Constipation Diseases 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- FFWOKTFYGVYKIR-UHFFFAOYSA-N physcion Chemical compound C1=C(C)C=C2C(=O)C3=CC(OC)=CC(O)=C3C(=O)C2=C1O FFWOKTFYGVYKIR-UHFFFAOYSA-N 0.000 description 4
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- NZPQWZZXRKZCDU-UHFFFAOYSA-N chrysophanol Natural products Cc1cc(O)c2C(=O)c3c(O)cccc3Oc2c1 NZPQWZZXRKZCDU-UHFFFAOYSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 description 2
- YDQWDHRMZQUTBA-UHFFFAOYSA-N Aloe emodin Chemical compound C1=CC=C2C(=O)C3=CC(CO)=CC(O)=C3C(=O)C2=C1O YDQWDHRMZQUTBA-UHFFFAOYSA-N 0.000 description 2
- 244000201986 Cassia tora Species 0.000 description 2
- 235000014552 Cassia tora Nutrition 0.000 description 2
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 2
- 241001478240 Coccus Species 0.000 description 2
- 239000010282 Emodin Substances 0.000 description 2
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 2
- 229920000926 Galactomannan Polymers 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 2
- UGNZSMZSJYOGNX-UHFFFAOYSA-N Isoviocristine Natural products O=C1C=C(C)C(=O)C2=CC3=CC(OC)=CC(O)=C3C(O)=C21 UGNZSMZSJYOGNX-UHFFFAOYSA-N 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 2
- WLXGUTUUWXVZNM-UHFFFAOYSA-N anthraglycoside A Natural products C1=C(C)C=C2C(=O)C3=CC(OC)=CC(O)=C3C(=O)C2=C1OC1OC(CO)C(O)C(O)C1O WLXGUTUUWXVZNM-UHFFFAOYSA-N 0.000 description 2
- JEUUNKOFKDUVMN-UHFFFAOYSA-N benzo[f]chromen-1-one Chemical compound C1=CC=CC2=C3C(=O)C=COC3=CC=C21 JEUUNKOFKDUVMN-UHFFFAOYSA-N 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 2
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 150000002596 lactones Chemical class 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- RVRLLYKHCMHGKV-UHFFFAOYSA-N norrubrofusarin Chemical compound C1=C(O)C=C2C=C(OC(C)=CC3=O)C3=C(O)C2=C1O RVRLLYKHCMHGKV-UHFFFAOYSA-N 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 229930000044 secondary metabolite Natural products 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 1
- 102000012440 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 1
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 1
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 1
- 241001225321 Aspergillus fumigatus Species 0.000 description 1
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000186018 Bifidobacterium adolescentis Species 0.000 description 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 1
- 235000009685 Crataegus X maligna Nutrition 0.000 description 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 1
- 235000009486 Crataegus bullatus Nutrition 0.000 description 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 1
- 235000009682 Crataegus limnophila Nutrition 0.000 description 1
- 240000000171 Crataegus monogyna Species 0.000 description 1
- 235000004423 Crataegus monogyna Nutrition 0.000 description 1
- 235000002313 Crataegus paludosa Nutrition 0.000 description 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000218671 Ephedra Species 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 244000168141 Geotrichum candidum Species 0.000 description 1
- 235000017388 Geotrichum candidum Nutrition 0.000 description 1
- 229920001706 Glucuronoxylan Polymers 0.000 description 1
- 229920002488 Hemicellulose Polymers 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- 241000186606 Lactobacillus gasseri Species 0.000 description 1
- 241000186604 Lactobacillus reuteri Species 0.000 description 1
- 241000235042 Millerozyma farinosa Species 0.000 description 1
- 241000228347 Monascus <ascomycete fungus> Species 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- RJGDLRCDCYRQOQ-UHFFFAOYSA-N anthrone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3CC2=C1 RJGDLRCDCYRQOQ-UHFFFAOYSA-N 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940091771 aspergillus fumigatus Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 150000002333 glycines Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229940001882 lactobacillus reuteri Drugs 0.000 description 1
- 230000001418 larval effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000028503 regulation of lipid metabolic process Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- FPNKCZKRICBAKG-UHFFFAOYSA-N rubrofusarin Chemical compound O1C(C)=CC(=O)C=2C1=CC1=CC(OC)=CC(O)=C1C=2O FPNKCZKRICBAKG-UHFFFAOYSA-N 0.000 description 1
- KLKFLNXANXGSIT-UHFFFAOYSA-N rubrofusarin Natural products O1C(C)=CC(=O)C2=C1C=C1C=C(O)C=C(OC)C1=C2O KLKFLNXANXGSIT-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
- C12P1/02—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using fungi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
- C12N1/145—Fungal isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
- C12P1/04—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/645—Fungi ; Processes using fungi
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/645—Fungi ; Processes using fungi
- C12R2001/66—Aspergillus
- C12R2001/685—Aspergillus niger
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Botany (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Alternative & Traditional Medicine (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a cassia seed fermentation product and application thereof, and relates to the technical field of microbial fermentation. The method comprises the following steps: (1) crushing 20-60 parts of semen cassiae, 10-30 parts of bean pulp and 10-30 parts of wheat bran, uniformly mixing, and sterilizing to obtain a mixture A for later use; (2) inoculating the mixture A into a bacterial liquid for fermentation treatment to obtain a fermentation product; (3) stirring and extracting the fermentation product with 50% ethanol solution, filtering, concentrating to obtain concentrated solution of the fermentation product, and spray drying the concentrated solution to obtain powder of the fermentation product; the interaction between the fermentation raw materials and the strains can be effectively improved by controlling the weight part ratio of the cassia seeds to the soybean meal in the implementation process, and the spore yield in the fermentation process is improved, so that the fermentation effect is improved; the interaction among microorganisms can be effectively improved by controlling the types and the addition amounts of the microorganisms and the additives, and the release amount of active ingredients of the medicament can be effectively improved.
Description
Technical Field
The invention relates to the technical field of microbial fermentation, in particular to a cassia seed fermentation product and application thereof.
Background
The fermentation method is a traditional method for processing Chinese medicines, and has the effects of saving medicines, reducing toxicity and enhancing efficiency. Although the traditional Chinese medicines are processed by fermentation, the conventional common procedures of decoction, steaming and soaking, refining and the like are changed, the curative effect of the medicines is obviously enhanced. For example, the traditional Chinese medicine fermented soybean is prepared by fermenting mulberry leaves or ephedra herb and the like, and the properties of the medicines can be obviously changed by adopting different culture media and treating the medicines by the same microorganisms, so the traditional Chinese medicines with different indications can be prepared by utilizing the characteristic. The modern traditional Chinese medicine fermentation technology is further innovative and developed on the traditional fermentation technology, combines traditional Chinese medicine fermentation with modern biotechnology such as bioengineering, microecology and the like, treats medicinal materials, and has wide prospect.
The fermentation has multiple functions in the processing of the traditional Chinese medicine, (1) the curative effect of the medicine can be enhanced: the traditional Chinese medicine fermentation processing is implemented by jointly fermenting microorganisms and traditional Chinese medicines, and secondary metabolites and medicinal ingredients generated by fermenting the microorganisms in the process are mutually cooperated to enhance the medicinal effect, so that the metabolic pathway is widened while the secondary metabolites and the medicaments act, and even obviously different effective ingredients are generated; (2) the extraction rate of the effective components is improved: the effective components of the Chinese herbal medicine are mostly wrapped in the cell walls of the Chinese herbal medicine, and the dense and hard cell walls are barriers for preventing the effective components of the medicine from being dissolved out of the cells and preventing the effective components from being absorbed in vivo. Therefore, the microorganism plays a certain role in extracting effective components, can secrete various extracellular enzymes aiming at the wall structure formed by different components, so that the formed compact structure is decomposed, the gaps among cells are enlarged, a channel is provided for the diffusion of substances inside and outside the cells, and the extraction rate and the absorption utilization rate of the effective components can be improved; (3) the toxicity of the medicine is reduced: traditional Chinese medicines are not completely harmless, and some medicines have certain toxicity and irritation due to various chemical components contained in the medicines, so that some side effects can occur when people use the medicines. Some medicinal materials are fermented, and the toxicity or irritation is obviously weakened, because the structure of toxic components is changed under the action of microorganisms, and the toxic components become low-toxicity or even non-toxic substances.
Traditional Chinese medicines are valuable wealth in China, but with the increasing development and unreasonable development and utilization of industrialization, medicinal plant resources are gradually deficient, and wild traditional Chinese medicinal materials are endangered, so that the improvement of the utilization rate of medicinal resources is one of effective ways for developing and utilizing traditional Chinese medicines. The fermentation method which is one of the research hotspots in the field of traditional Chinese medicine processing has the advantages of changing the property of the medicine, improving the curative effect, reducing the toxic and side effect and the like, and widens the research range for further research and development of abundant medicinal resources in China and even development of the traditional Chinese medicine industry.
Semen Cassiae is dried mature seed of Cassia tora or Cassia tora L of Leguminosae, and has effects of clearing heat, improving eyesight, and loosening bowel to relieve constipation. Pharmacological experiments prove that the cassia seed not only has better effects of reducing blood fat, resisting atherosclerosis and the like, but also has the effects of reducing blood pressure, enhancing the immunity of the organism, resisting aging and the like. The cassia seed contains a plurality of chemical components such as anthraquinone, naphthopyrone, polysaccharide and the like, wherein the anthraquinone compound mainly comprises emodin, chrysophanol, physcion and the like, and has the effects of resisting inflammation and bacteria, resisting oxidation, resisting tumors, reducing blood fat, protecting nerves, protecting liver and eyes, relaxing bowels and promoting urination, killing larval activity, and inhibiting acetylcholinesterase and beta-secretase; naphthopyrones mainly include rubrofusarin, nor-rubrofusarin, cassia seed lactone, iso-cassia seed lactone, cassia anthranone, rhein-9-anthracenone, etc., and have antidiabetic, antibacterial, and antiestrogenic effects; the polysaccharide compound mainly comprises pectic polysaccharide, hemicellulose, arabinoglucan, galactomannan, glucuronoxylan, neutral galactomannan and the like, has the functions of resisting oxidation, immunity and tumors, treating diabetes and complications, reducing blood pressure and blood fat, regulating gastrointestinal tracts and protecting livers and eyes, and the cassia seed is one of the first medicines which are both edible and medicinal and published by the Ministry of health of China.
Chinese patent application 201811439573.9 discloses a semen Cassiae composition with blood lipid lowering effect, which is prepared by mixing and fermenting semen Cassiae, fructus crataegi, semen glycines and rice twice, and its preparation process is: firstly inoculating the semen cassiae, the hawthorn and the soybeans into bacillus natto according to a formula ratio for fermentation, adding rice and monascus into the prepared fermentation product for secondary fermentation, wherein the active components in the obtained semen cassiae composition have an obvious synergistic effect, and play a role in actively reducing blood fat in multiple aspects such as reduction of endogenous lipid synthesis, promotion of lipid transportation and excretion, regulation of lipid metabolism and the like, and the semen cassiae composition is safe, non-toxic and harmless.
Chinese patent application 201410692371.0 discloses a composition for improving, treating or preventing constipation containing a lactic acid bacteria fermentation product of cassia seed as an active ingredient, which is highly safe for long-term use and has a low possibility of causing side effects as a crude drug, and which can be used as a pharmaceutical composition for treating or preventing constipation or a health functional food for improving or preventing constipation, and a method for producing the same.
According to the above description of the prior art, the main purpose is to achieve the synergistic effect of the medicinal components in the composition, but there is no description on how to improve the release rate of the effective components in the medicinal components, and the content of various effective components in the fermented cassia seed product obtained by adopting various microbial fermentation methods in the implementation process of the invention is obviously improved.
Disclosure of Invention
Aiming at the defects in the prior art, the invention aims to provide the cassia seed fermented product and the application thereof.
In one aspect, the invention provides a cassia seed leavening, which comprises the following steps:
(1) crushing the fermentation raw materials, uniformly mixing and sterilizing to obtain a mixture A for later use;
(2) inoculating the mixture A obtained in the step (1) into a bacterial liquid for fermentation treatment to obtain a fermentation product;
(3) and (3) stirring and extracting the fermentation product obtained in the step (2) by using a 50% ethanol solution, filtering and concentrating to obtain a fermentation product extraction concentrated solution, and then performing spray drying on the concentrated solution to obtain fermentation product extraction powder.
The fermentation raw material in the step (1) is one or more of cassia seed, soybean meal and wheat bran;
preferably, the fermentation raw materials in the step (1) are cassia seeds, soybean meal and wheat bran;
the fermentation raw material in the step (1) comprises the following components in parts by weight: 20-60 parts of cassia seed, 10-30 parts of bean pulp and 10-30 parts of wheat bran.
Preferably, the fermentation raw material in the step (1) comprises the following components in parts by weight: 30-50 parts of cassia seed, 15-25 parts of bean pulp and 15-25 parts of wheat bran.
Still preferably, the fermentation raw material in the step (1) comprises, in parts by weight: 40-50 parts of cassia seed, 18-22 parts of bean pulp and 20-25 parts of wheat bran.
In some embodiments, the weight ratio of the cassia seeds to the soybean meal is 1-6: 1; preferably, the weight part ratio of the cassia seeds to the soybean meal is 2-5: 1; preferably, the weight part ratio of the cassia seeds to the soybean meal is 4-5: 1.
The bacterial strain in the bacterial liquid in the step (2) is selected from one or more of aspergillus niger, geotrichum candidum, aspergillus fumigatus, lactic acid such as coccus, penicillium, lactobacillus reuteri, lactobacillus gasseri, lactobacillus salivarius, bifidobacterium adolescentis, pichia pastoris powder and kluyveromyces marxianus;
preferably, the strain is selected from one or more of aspergillus niger, lactic acid such as coccus, lactobacillus salivarius, pichia farinosa and kluyveromyces marxianus;
still more preferably, the species is selected from the group consisting of Aspergillus niger, Lactobacillus salivarius and Kluyveromyces marxianus.
Further preferably, the ratio of the addition amount of the lactobacillus salivarius, the kluyveromyces marxianus and the aspergillus niger is 5-10: 3-5: 1; preferably 8 to 10: 4-5: 1; more preferably 9 to 10: 5: 1; more preferably 10: 5: 1.
the addition amount of the strain is 5-10% of the fermentation raw material, preferably, the addition amount of the strain is 5%, 6%, 7%, 8%, 9% or 10% of the fermentation raw material.
In some preferred embodiments, the bacterial liquid further contains an auxiliary agent, wherein the auxiliary agent is prepared from the following components in a mass ratio of 2-3: 1 sucrose and skim milk.
The addition amount of the auxiliary agent is 2-5% of the fermentation raw material; preferably, the addition amount of the auxiliary agent is 2%, 3%, 4% or 5% of the fermentation raw material.
The fermentation time is 36-48 hours.
In the implementation process, the fact that the survival rate of the strains can be effectively improved by adding a certain content of the auxiliary agent into the bacterial liquid in the fermentation process is unexpectedly found, so that the fermentation effect of microorganisms is improved, and the release rate of the effective components of the medicine is improved.
On the other hand, the invention also provides an application of the cassia seed fermentation product as an effective component in preparing a pharmaceutical composition for resisting inflammation and bacteria, resisting tumors, reducing blood fat and protecting liver and eyes.
The pharmaceutical composition can be prepared into powder, granules, tablets, capsules or syrup and the like.
The pharmaceutical composition also comprises a flavoring agent, a filling agent or an emulsifying agent which is acceptable on health-care food.
The invention provides a cassia seed leavening, which specifically comprises the following steps:
(1) crushing 20-60 parts of semen cassiae, 10-30 parts of bean pulp and 10-30 parts of wheat bran, uniformly mixing, and sterilizing to obtain a mixture A for later use;
(2) inoculating the mixture A obtained in the step (1) in a mixture with the addition amount ratio of 5-10: 3-5: 1, fermenting in a bacterial liquid of a mixed strain of lactobacillus salivarius, kluyveromyces marxianus and aspergillus niger to obtain a fermentation product;
(3) and (3) stirring and extracting the fermentation product obtained in the step (2) by using a 50% ethanol solution, filtering and concentrating to obtain a fermentation product extraction concentrated solution, and then performing spray drying on the concentrated solution to obtain fermentation product extraction powder.
The number of viable bacteria of Aspergillus niger, Lactobacillus salivarius and Kluyveromyces marxianus is 1 × 104-1×106CFU/mL。
The addition amount of the strain is 5-10% of the fermentation raw material, preferably, the addition amount of the strain is 5%, 6%, 7%, 8%, 9% or 10% of the fermentation raw material.
In some preferred embodiments, the bacterial liquid further contains an auxiliary agent, wherein the auxiliary agent is prepared from the following components in a mass ratio of 2-3: 1 sucrose and skim milk; preferably, the mass ratio of the auxiliary agent is 2: 1 or 3: 1 sucrose and skim milk.
On the other hand, the invention also provides an application of the cassia seed fermentation product as an effective component in preparing a pharmaceutical composition for resisting inflammation and bacteria, resisting tumors, reducing blood fat and protecting liver and eyes.
The pharmaceutical composition can be prepared into powder, granules, tablets, capsules or syrup and the like.
The pharmaceutical composition also comprises a flavoring agent, a filling agent or an emulsifying agent which is acceptable on health-care food.
Compared with the prior art, the invention has the beneficial effects that:
(1) according to the invention, the ratio of the weight parts of the cassia seeds to the soybean meal in the fermentation raw materials is controlled to be 1-6:1 in the implementation process, so that the interaction between the fermentation raw materials and the strains can be effectively improved, the spore yield in the fermentation process is improved, and the fermentation effect is improved;
(2) the invention uses mixed strains for fermentation, and controls the adding amount ratio of the microorganisms lactobacillus salivarius, kluyveromyces marxianus and aspergillus niger to be 5-10: 3-5: 1, the interaction among microorganisms can be effectively improved by adopting mixed strain fermentation, the fermentation efficiency is improved, and the fermentation time is shortened;
(3) in order to ensure that the fermentation effect is better and the survival time of microorganisms is longer, a certain amount of auxiliary agents are added into the bacterial liquid, namely the mass ratio of the auxiliary agents is 2-3: 1, the cane sugar and the skim milk can obviously improve the survival time of microorganisms, improve the fermentation effect and promote the full release of the effective components of the medicine.
Detailed Description
The present invention is described below by way of specific embodiments, and unless otherwise specified, the technical means used in the present invention are all methods well known to those skilled in the art. In addition, the embodiments should be considered illustrative, and not restrictive, of the scope of the invention, which is defined solely by the claims. It will be apparent to those skilled in the art that various changes or modifications can be made in the material composition and the amount of the embodiments without departing from the spirit and scope of the invention.
Wherein, Lactobacillus salivarius (Lactobacillus salivarius), the number is: CICCNo.23174, purchased from China center for Industrial culture Collection of microorganisms;
kluyveromyces marxianus (kluyveromyces marxianus), no: CICCNo.1276, which is purchased from China center for culture Collection of Industrial microorganisms;
aspergillus niger (Aspergillus niger), number CICCNo.2108, purchased from China center for Industrial culture Collection of microorganisms.
In addition, the raw materials used in the present invention, i.e., reagents, are commercially available, and the units used in the present invention may be: parts, percentages, grams or kilograms, as desired.
EXAMPLE 1 fermentation product of Cassia seed
The method specifically comprises the following steps:
(1) crushing 20 parts of semen cassiae, 10 parts of bean pulp and 10 parts of wheat bran, uniformly mixing, and sterilizing to obtain a mixture A for later use;
(2) inoculating the mixture A obtained in the step (1) in a mixture with an addition ratio of 5: 3: 1, adding 3.6 parts of auxiliary agent-containing bacterial liquid of lactobacillus salivarius, kluyveromyces marxianus and aspergillus niger, and performing fermentation treatment to obtain a fermentation product;
(3) and (3) stirring and extracting the fermentation product obtained in the step (2) for 1 hour by using a 50% ethanol solution, filtering the obtained extract, concentrating the filtrate to obtain a fermentation product extract concentrated solution, and then performing spray drying on the concentrated solution to obtain fermentation product extract powder.
The auxiliary agent in the bacterial liquid is 1.2 parts by mass ratio of 2: 1 sucrose and skim milk.
Example 2A fermentation product of Cassia seed
The method specifically comprises the following steps:
(1) crushing 60 parts of semen cassiae, 30 parts of bean pulp and 30 parts of wheat bran, uniformly mixing, and sterilizing to obtain a mixture A for later use;
(2) inoculating the mixture A obtained in the step (1) in a mixture with an addition ratio of 5: 5:1, adding 10.56 parts of auxiliary agent into the bacterial liquid of the lactobacillus salivarius, the Kluyveromyces marxianus and the Aspergillus niger, and performing fermentation treatment to obtain a fermentation product;
(3) and (3) stirring and extracting the fermentation product obtained in the step (2) for 2 hours by using a 50% ethanol solution, filtering the obtained extract, concentrating the filtrate to obtain a fermentation product extract concentrated solution, and then performing spray drying on the concentrated solution to obtain fermentation product extract powder.
The auxiliary agent in the bacterial liquid is 2.4 parts by mass ratio of 3: 1 sucrose and skim milk.
EXAMPLE 3 fermentation product of Cassia seed
The method specifically comprises the following steps:
(1) crushing 60 parts of semen cassiae, 10 parts of bean pulp and 15 parts of wheat bran, uniformly mixing, and sterilizing to obtain a mixture A for later use;
(2) inoculating the mixture A obtained in the step (1) in a mixture with an addition ratio of 10: 3: 1, adding 8.33 parts of auxiliary agent-containing bacterial liquid into the lactobacillus salivarius, the kluyveromyces marxianus and the aspergillus niger, and performing fermentation treatment to obtain a fermentation product;
(3) and (3) stirring and extracting the fermentation product obtained in the step (2) for 1.5 hours by using a 50% ethanol solution, filtering the obtained extract, concentrating the filtrate to obtain a fermentation product extract concentrated solution, and then performing spray drying on the concentrated solution to obtain fermentation product extract powder.
The auxiliary agent in the bacterial liquid is 3.4 parts by mass ratio of 3: 1 sucrose and skim milk.
Example 4A fermentation product of Cassia seed
The method specifically comprises the following steps:
(1) crushing 50 parts of semen cassiae, 10 parts of bean pulp and 25 parts of wheat bran, uniformly mixing, and sterilizing to obtain a mixture A for later use;
(2) inoculating the mixture A obtained in the step (1) in a mixture with an addition ratio of 10: 5:1, adding 6.8 parts of auxiliary agent-containing bacterial liquid into the lactobacillus salivarius, the kluyveromyces marxianus and the aspergillus niger, and performing fermentation treatment to obtain a fermentation product;
(3) and (3) stirring and extracting the fermentation product obtained in the step (2) for 2 hours by using a 50% ethanol solution, filtering the obtained extract, concentrating the filtrate to obtain a fermentation product extract concentrated solution, and then performing spray drying on the concentrated solution to obtain fermentation product extract powder.
The auxiliary agent in the bacterial liquid is 4.25 parts by mass ratio of 3: 1 sucrose and skim milk.
Comparative examples 1 to 6A fermented product of Cassia seed
The difference from example 4 is that: the specific data are shown in Table 1 below (unit: parts)
TABLE 1
The preparation methods of comparative examples 1 to 6 were the same as those of example 4 except that the contents of the respective components were different.
Comparative example 7
The difference from example 4 is that: the addition ratio of the lactobacillus salivarius, the kluyveromyces marxianus and the aspergillus niger is 2: 5: 3, namely 1.36 parts of lactobacillus salivarius, 3.4 parts of kluyveromyces marxianus and 2.04 parts of aspergillus niger, and the other operations and steps are the same as the example 4.
Comparative example 8
The difference from example 4 is that: the mass ratio of the sucrose to the skim milk in the auxiliary agent is 0.7: 1, namely 1.75 parts of cane sugar and 2.5 parts of skim milk, and the other operations and steps are the same as those in example 4.
Comparative example 9
The difference from example 4 is that: the auxiliary agent only contains cane sugar, namely 4.25 parts of cane sugar, and other operations and steps are the same as those of the example 4.
Comparative example 10
The difference from example 4 is that: the weight portion ratio of the cassia seed to the bean pulp is 0.5: 1, namely 20 parts of cassia seeds and 40 parts of soybean meal, and the other operations are the same as the steps in the example 4.
Comparative example 11
The difference from example 4 is that: the weight portion ratio of the cassia seed to the soybean meal is 9: 1, namely 54 parts of cassia seeds and 6 parts of bean pulp, and the other operations are the same as the steps in the example 4.
Test example 1 viable cell count detection
And (3) taking fermentation products with the same volume at time nodes of 0 hour, 6 hours, 12 hours, 24 hours and 48 hours of fermentation respectively, and measuring the number of viable bacteria in the fermentation products, wherein specific detection results are shown in the following table 2.
TABLE 2 viable count test
According to the detection data in the table 2, the number of viable bacteria is obviously increased after 48 hours of fermentation in the embodiment of the invention, the interaction between the fermentation raw materials and the strains can be effectively improved by controlling the mass ratio of the components, and the spore yield in the fermentation process is improved, so that the fermentation effect is improved, while the comparative example changes the mass ratio of the components out of the protection range disclosed by the invention, or reduces the number of viable bacteria which can obviously influence the fermentation process by one component, so that the fermentation effect is influenced.
Test example 2 detection of active ingredient of drug
The detection method comprises the following steps: performing ultrasonic extraction for 30 minutes at room temperature by taking methanol as an extraction solvent according to a sample before fermentation of the semen gmelini, fermentation products obtained in examples 1-4 and comparative examples 1-11, wherein the material-liquid ratio is 1:10, filtering an extracting solution by using a filter membrane, and obtaining a filtrate to be tested for later use;
a chromatographic column: c18-ODS reverse phase column (250 mm. times.4.6 mm,5 μm); mobile phase: methanol (A) -0.1% phosphoric acid water solution (B), gradient elution (volume fraction of A is 63% in 0-33min, 63-75% in 33-40min, and 75-95% in 40-60 min); flow rate: 1 mL. min-1(ii) a Column temperature: 25 ℃; detection wavelength: 280 nm. The separation degree of each peak is more than 1.5, the theoretical plate number is more than or equal to 3000 calculated according to chrysophanol peak, and the detection results are shown in tables 3 and 4.
Percent change%
TABLE 3 measurement results (mg. g) of anthraquinone component content in the cassia seeds before fermentation and the cassia seeds after fermentation in examples 1 to 4 and comparative examples 1 to 6-1)
According to the detection data in the table 3, the total increase trend of the anthraquinone content after fermentation can be seen, but the increase amplitudes of aloe-emodin, rhein and emodin in the examples 1-4 are relatively small, and are only increased by about 10%, the chrysophanol is increased by about 120%, and the physcion is increased by about 40%, which indicates that the fermentation method provided by the invention is favorable for releasing the active ingredient anthraquinone, but according to the fermentation result, the free anthraquinone content after fermentation is in the increase trend, which indicates that the cassia seed is favorable for increasing the active ingredient anthraquinone aglycone through fermentation; according to the detection data of the comparative examples 1 to 6, the extraction rate of the effective components in the cassia seeds is obviously reduced compared with the examples because the effective components in the cassia seeds are released and obviously influenced by reducing one component in the components.
TABLE 4 measurement results (mg. g) of anthraquinone components in fermented cassia seeds of comparative examples 7 to 11-1)
According to the detection data in the above table 4, it can be seen that when the mass ratio of two or more ingredients in the fermentation components is not within the protection range of the present invention, the content of the effective ingredients in the obtained fermented product is increased compared with that before fermentation, but the increase is reduced compared with that in the example 4, so that the fermentation effect is best only when the ingredients and contents disclosed by the present invention are used in the fermentation process, the content release rate of the effective ingredients in the obtained product is high, and further the extraction rate is high.
The above-mentioned embodiments only express several embodiments of the present invention, and the description thereof is more specific and detailed, but not construed as limiting the scope of the present invention. It should be noted that, for a person skilled in the art, several variations and modifications can be made without departing from the inventive concept, which falls within the scope of the present invention. Therefore, the protection scope of the present patent shall be subject to the appended claims.
Claims (5)
1. A semen cassiae fermentation product is characterized in that: the preparation method comprises the following steps:
(1) crushing the fermentation raw materials, uniformly mixing and sterilizing to obtain a mixture A for later use;
(2) inoculating a fermentation strain into the mixture A obtained in the step (1) for fermentation treatment to obtain a fermentation product;
(3) stirring and extracting the fermentation product obtained in the step (2) by using a 50% ethanol solution, filtering and concentrating to obtain a fermentation product extraction concentrated solution, and then spray-drying the concentrated solution to obtain fermentation product extraction powder;
the fermentation raw materials in the step (1) comprise the following components in parts by weight: 20-60 parts of cassia seed, 10-30 parts of bean pulp and 10-30 parts of wheat bran;
the weight part ratio of the cassia seeds to the soybean meal is 1-6: 1;
the strains are lactobacillus salivarius, kluyveromyces marxianus and aspergillus niger;
the addition ratio of the lactobacillus salivarius, the Kluyveromyces marxianus and the Aspergillus niger is 5-10: 3-5: 1;
the bacterial liquid in the step (2) also contains an auxiliary agent, wherein the auxiliary agent is prepared from the following components in a mass ratio of 2-3: 1 sucrose and skim milk.
2. The fermentation product of cassia seed according to claim 1, characterized in that: the fermentation raw materials in the step (1) comprise the following components in parts by weight: 30-50 parts of cassia seed, 15-25 parts of bean pulp and 15-25 parts of wheat bran.
3. The fermentation product of cassia seed according to claim 1, characterized in that: the addition amount of the strain is 5-10% of the fermentation raw material.
4. The fermentation product of cassia seed according to claim 1, characterized in that: the addition amount of the auxiliary agent is 2-5% of the fermentation raw material.
5. The use of the fermentation product of cassia seed of claim 1 in the preparation of a pharmaceutical composition for anti-inflammatory, anti-bacterial, anti-tumor, blood lipid lowering, liver protection and eye protection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010293704.8A CN111454993B (en) | 2020-04-15 | 2020-04-15 | Semen cassiae fermentation product and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010293704.8A CN111454993B (en) | 2020-04-15 | 2020-04-15 | Semen cassiae fermentation product and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111454993A CN111454993A (en) | 2020-07-28 |
| CN111454993B true CN111454993B (en) | 2021-01-15 |
Family
ID=71675030
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010293704.8A Active CN111454993B (en) | 2020-04-15 | 2020-04-15 | Semen cassiae fermentation product and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111454993B (en) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1308277C (en) * | 2005-08-30 | 2007-04-04 | 华南师范大学 | Method of extracting anthraquinone analog compound from traditional Chinese medicine cassia seed |
| KR100962587B1 (en) * | 2007-10-02 | 2010-06-11 | 동국대학교 산학협력단 | A method for fermentation of natural plants and herbal medicines, a fermented product prepared therefrom and a paharmaceutical composition, a cosmetic compositon and a food composition comprising the product |
| KR20170062563A (en) * | 2015-11-27 | 2017-06-08 | 재단법인 한국한방산업진흥원 | Method of increasing antioxidant and anti-inflammatory activity of Cassiae semen and the fermented extract having increased activity by that |
| CN109206308A (en) * | 2018-09-19 | 2019-01-15 | 西安绿海生物科技有限公司 | A method of preparing rheum emodin and Physcion from cassia seed |
-
2020
- 2020-04-15 CN CN202010293704.8A patent/CN111454993B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN111454993A (en) | 2020-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101370386B1 (en) | Preparation method of fermented red ginseng using effective micro-organisms | |
| CN106798252B (en) | Natto product with effects of regulating intestines and stomach, reducing blood fat and dissolving thrombus | |
| KR101240192B1 (en) | Lactobacillus acidophilus K-59, extracts from ginseng-fermented products using K-59 for improving insulin secretion and manufacturing method thereof | |
| KR101339706B1 (en) | A compound for immune strengthen inclusion reducing the bitterness of red ginseng, the extract of immune, and the probiotics | |
| KR20170061959A (en) | Preparation method of fermented ginseng and fermented black-red ginseng with active ginsenoside heightening rate absorption | |
| KR101851195B1 (en) | Fermented mulberry leaves, femented mulberry leaves extract and use there of | |
| CN112617182B (en) | Plant enzyme composition for weight management and preparation method thereof | |
| KR102095889B1 (en) | Composition for preventing or treating climacteric disorder comprising Monascus sp.-fermented Glycyrrhiza uralensis | |
| KR101372400B1 (en) | A manufacturing method of red ginseng staf4h with enhanced trace ginsenoside | |
| KR20100079874A (en) | Preparation method of fermented ginseng or fermented red ginseng with active ginsenoside heightening absroption rate using lactic acid bacteria | |
| KR20060000488A (en) | Composition containing ginseng extract comprising saponin derivatives isolated from ginseng radix and ginseng for preventing and treating scratching diseases | |
| KR20160126591A (en) | Method of producing ginseng fermented extract, Ginseng fermented extract produced by the same and Health functional foods comprising the same | |
| CN111454993B (en) | Semen cassiae fermentation product and application thereof | |
| CN105640971B (en) | Application of the total saposins in terms of preparing auxiliary hyperglycemic drug in prematurity Fructus Monordicae extract | |
| KR101139508B1 (en) | Fermented ginseng materials comprising bio-conversion compound K and manufacturing method, functional rice wine using the same | |
| CN110859869A (en) | A composition for preventing and treating cardiovascular and cerebrovascular diseases, and its preparation method | |
| CN114507297B (en) | Preparation and application of polysaccharide extract of birch mushroom | |
| KR100848686B1 (en) | A FERMENTED GINSENG COMPOSITION STRENGTHENED SIMULTANEOUSLY WITH γ-AMINOBUTYRIC ACID AND BIOCONVERSION SAPONIN BY LACTIC ACID BACTERIA | |
| CN109430476A (en) | Tea ferment drink and preparation method thereof with defaecation ease constipation function | |
| KR102303125B1 (en) | Method for producing double-coating red ginseng granule with enhanced ginsenoside content and improved preservability | |
| KR102132537B1 (en) | Platycodon grandiflorum Liquid composition for stick-type container having increased ginsenosides of human body absorption type, and preparation method thereof | |
| KR102106018B1 (en) | Method For Producing Steaming Ginseng Berry Fermented Extracts Having Preventive and Improving Effects of Liver Damage | |
| CN111838551B (en) | Flavone fermentation product, preparation method thereof and application thereof in blood sugar regulation | |
| CN118077902B (en) | Weight-losing composition containing probiotics and preparation method thereof | |
| KR102545583B1 (en) | Method for producing double-coating red ginseng granule with enhanced ginsenoside content and improved preservability |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A fermentation product of cassia seed and its application Effective date of registration: 20210625 Granted publication date: 20210115 Pledgee: Wuhan Rural Commercial Bank Co.,Ltd. Caidian sub branch Pledgor: WUHAN SENLAN BIOTECHNOLOGY Co.,Ltd. Registration number: Y2020980003848 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Granted publication date: 20210115 Pledgee: Wuhan Rural Commercial Bank Co.,Ltd. Caidian sub branch Pledgor: WUHAN SENLAN BIOTECHNOLOGY CO.,LTD. Registration number: Y2020980003848 |